- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00863785
Treatment of Severe Alcoholic Hepatitis With Corticoids Plus N Acetyl Cysteine Versus Corticoids Alone (HAA-NAC)
October 19, 2009 updated by: Centre Hospitalier Universitaire, Amiens
Treatment of Acute Severe Alcoholic Hepatitis With Corticoids Plus N Acetyl Cysteine Versus Corticoids Alone: a French Multicentre Randomized Controlled Study.
35% of Acute Alcoholic Hepatitis patients (AAH) do not respond to corticoids and died after 6 months.
Chronic alcohol abuse depletes glutathione in the hepatocytes and makes the latter more sensitive to excessive TNFα levels.
Re-establishment of a stock of antioxidants by administration of a precursor (N-acetyl cysteine, NAC) in combination with corticoids (C) could make the hepatocytes more resistant and improve survival.
The investigators' study's primary endpoint was improvement of survival at 6 months.
The secondary endpoints were survival at 1 and 3 months, tolerance of NAC and a drop in blood bilirubin levels at D7
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
AAH patients (Maddrey score > 32 and compatible histological results) should centrally randomized into the C-NAC or C groups.
Both groups received 4 weeks of prednisolone treatment, plus NAC for the combination therapy group (D1: 150, 50 and 100 mg/kg in 250, 500 and 1000 mL of 5% glucose-saline (G5%) respectively, at t=30 minutes, 4 and 16 hours; D2 to D5, 100 mg/kg in 1000 mL of G5%).
Group C received 1000 mL of G5%, D1-5
Study Type
Interventional
Enrollment (Actual)
174
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Abbeville, France
- Centre Hospitalier d'Abbeville
-
Beauvais, France, 60000
- Centre Hospitalier Beauvais
-
Besancon, France, 25030
- Centre Hospitalier Universitaire de Besançon
-
Caen, France, 14000
- Centre Hospitalier Universitaire de Caen
-
Cambrai, France
- Centre Hospitalier de Cambrai
-
Compiegne, France
- Centre Hospitalier de Compiegne
-
Lens, France
- Centre Hospitalier de LENS
-
Paris, France
- Centre hospitalier Saint-Antoine
-
Paris, France
- Centre Hospitalier Universitaire Pitié-Salpétrière
-
Reims, France
- Centre Hospitalier Universitaire de Reims
-
Rouen, France, 76031
- Centre Hospitalier Universitaire de Rouen
-
Saint-quentin, France
- Centre Hospitalier de Saint-Quentin
-
Valenciennes, France
- Centre Hospitalier de Valenciennes
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patient consent
- Chronic alcohol intake in the last 3 to 6 months
- Maddrey score ≥ 32
- Liver histology compatible
Exclusion Criteria:
- Hepato renal syndrome
- Hepatocarcinoma
- Recent variceal haemorrhage
- Recent bacterial infections
- Other liver diseases associated (HCV, HBV, hemochromatosis, AIH)
- Cancers or cardiac and respiratory, HIV infection
- NAC Allergy
- No patient consent
- Acetaminophen intoxication
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Corticoids plus N Acetyl Cysteine
40 mg/d prednisolone N Acetyl Cysteine infusion 150mg/kg in 30 minutes then 50 mg/kg in 4 h then 100mg/kg in 16 h and finally 100mg/d2 to d5
|
40 mg/d prednisolone N Acetyl Cysteine infusion 150mg/kg in 30 minutes then 50 mg/kg in 4 h then 100mg/kg in 16 h and finally 100mg/d2 to d5
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Survival at one, three and six months
Time Frame: six months
|
six months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
bilirubin decrease at day seven survival at one and three months nac tolerance side effects
Time Frame: one, three and six months
|
one, three and six months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Director: Phillippe DOMY, Centre Hospitalier Universitaire, Amiens
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2004
Primary Completion (ACTUAL)
August 1, 2009
Study Completion (ACTUAL)
September 1, 2009
Study Registration Dates
First Submitted
March 17, 2009
First Submitted That Met QC Criteria
March 17, 2009
First Posted (ESTIMATE)
March 18, 2009
Study Record Updates
Last Update Posted (ESTIMATE)
October 20, 2009
Last Update Submitted That Met QC Criteria
October 19, 2009
Last Verified
October 1, 2009
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Chemically-Induced Disorders
- Digestive System Diseases
- Alcohol-Related Disorders
- Substance-Related Disorders
- RNA Virus Infections
- Virus Diseases
- Infections
- Liver Diseases
- Hepatitis, Viral, Human
- Enterovirus Infections
- Picornaviridae Infections
- Liver Diseases, Alcoholic
- Alcohol-Induced Disorders
- Hepatitis
- Hepatitis A
- Hepatitis, Alcoholic
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Protective Agents
- Respiratory System Agents
- Antioxidants
- Antidotes
- Free Radical Scavengers
- Expectorants
- Acetylcysteine
- N-monoacetylcystine
Other Study ID Numbers
- PHRC R04 - Dr NGUYEN-KHAC
- AFSSAPS 040276
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alcoholic Hepatitis
-
Seoul St. Mary's HospitalGlaxoSmithKlineTerminatedNASH (Non-alcoholic Steato-hepatitis)
-
University Hospital, LilleRecruitingAlcoholic Liver Disease | Severe Alcoholic Hepatitis | Alcoholic CirrhosisFrance
-
HepQuant, LLCWithdrawnSevere Alcoholic HepatitisUnited States
-
Vital Therapies, Inc.CompletedAcute Alcoholic HepatitisUnited States, Spain, Australia, United Kingdom
-
Vital Therapies, Inc.TerminatedAcute Alcoholic HepatitisUnited States, Spain, United Kingdom, Germany, Austria, Ireland
-
Institute of Liver and Biliary Sciences, IndiaNot yet recruiting
-
Institute of Liver and Biliary Sciences, IndiaUnknownSevere Alcoholic HepatitisIndia
-
Vital Therapies, Inc.TerminatedSevere Acute Alcoholic HepatitisUnited States, Spain, United Kingdom, Germany
-
CHU de ReimsCompletedSevere Alcoholic HepatitisFrance
-
MedRegen LLCNot yet recruitingAlcoholic Hepatitis | Acute Alcoholic Hepatitis
Clinical Trials on Corticoids plus N Acetyl Cysteine
-
Universidade Estadual de MaringáUnknownBipolar DisorderBrazil
-
Minia UniversityUnknown
-
University of Colorado, DenverWithdrawn
-
Aga Khan UniversityNational Institute of Liver & GI Diseases, PakistanNot yet recruiting
-
Asian Institute of Gastroenterology, IndiaCompleted
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)WithdrawnHead and Neck Cancer
-
Ain Shams UniversityRecruiting
-
Imam Khomeini HospitalTehran Heart CenterUnknownRadiographic Contrast Agent Nephropathy | Chronic Kidney Disease Stage 2Iran, Islamic Republic of
-
Nemours Children's ClinicCompletedObesity | Cardiovascular Disease | Nonalcoholic Fatty Liver DiseaseUnited States
-
Washington University School of MedicineSuspendedDiabetes Mellitus | Peripheral Arterial Disease | Critical Limb Ischemia | Lower Limb Amputation KneeUnited States